- Markets
- Healthcare
- VIVOBIOT
VIVOBIOT
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Vivo Bio Tech Launches Large Animal Facility, Operations Already Commenced
Jan 13 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
LAUNCHES LARGE ANIMAL FACILITY, OPERATIONS ALREADY COMMENCED
Source text: ID:nBSE21BrNV
Further company coverage: VIVO.BO
(([email protected];;))
Jan 13 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
LAUNCHES LARGE ANIMAL FACILITY, OPERATIONS ALREADY COMMENCED
Source text: ID:nBSE21BrNV
Further company coverage: VIVO.BO
(([email protected];;))
Vivo Bio Tech Approves Preferential Issue Of Warrants Upto 450 Million Rupees
Jan 9 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
VIVO BIO TECH - APPROVED PREFERENTIAL ISSUE OF WARRANTS UPTO 450 MILLION RUPEES
Source text: ID:nBSE87ccwJ
Further company coverage: VIVO.BO
(([email protected];))
Jan 9 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
VIVO BIO TECH - APPROVED PREFERENTIAL ISSUE OF WARRANTS UPTO 450 MILLION RUPEES
Source text: ID:nBSE87ccwJ
Further company coverage: VIVO.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vivo Bio Tech do?
Vivo Bio Tech Ltd is a contract research company specializing in biotechnology and pharmaceutical drug discovery services. They offer a comprehensive range of services including insilico design, wet lab research, preclinical studies, and clinical trials.
Who are the competitors of Vivo Bio Tech?
Vivo Bio Tech major competitors are Jeevan Scientific, Zenotech Laboratorie, Dishman Carbogen Amc, Sun Pharma Adv. Res, Syngene Internation., Suven Life Sciences, Hikal. Market Cap of Vivo Bio Tech is ₹71 Crs. While the median market cap of its peers are ₹3,329 Crs.
Is Vivo Bio Tech financially stable compared to its competitors?
Vivo Bio Tech seems to be less financially stable compared to its competitors. Altman Z score of Vivo Bio Tech is 1.62 and is ranked 7 out of its 8 competitors.
Does Vivo Bio Tech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vivo Bio Tech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vivo Bio Tech allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Short Term Loans & Advances
How strong is Vivo Bio Tech balance sheet?
Vivo Bio Tech balance sheet is weak and might have solvency issues
Is the profitablity of Vivo Bio Tech improving?
The profit is oscillating. The profit of Vivo Bio Tech is ₹6.96 Crs for TTM, ₹2.53 Crs for Mar 2024 and ₹2.65 Crs for Mar 2023.
Is the debt of Vivo Bio Tech increasing or decreasing?
The debt of Vivo Bio Tech is decreasing. Latest debt of Vivo Bio Tech is ₹56.51 Crs as of Sep-24. This is less than Mar-24 when it was ₹70.53 Crs.
Is Vivo Bio Tech stock expensive?
Vivo Bio Tech is not expensive. Latest PE of Vivo Bio Tech is 10.23, while 3 year average PE is 19.55. Also latest EV/EBITDA of Vivo Bio Tech is 6.11 while 3yr average is 6.34.
Has the share price of Vivo Bio Tech grown faster than its competition?
Vivo Bio Tech has given lower returns compared to its competitors. Vivo Bio Tech has grown at ~-6.0% over the last 7yrs while peers have grown at a median rate of 0.94%
Is the promoter bullish about Vivo Bio Tech?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 40.85% and last quarter promoter holding is 38.88%.
Are mutual funds buying/selling Vivo Bio Tech?
There is Insufficient data to gauge this.